Business Description
Milestone Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA59935V1076
Description
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.42 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 2.25 | |||||
| Debt-to-EBITDA | -1.38 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.3 | |||||
| 3-Year EPS without NRI Growth Rate | 6.5 | |||||
| 3-Year FCF Growth Rate | 14.4 | |||||
| 3-Year Book Growth Rate | -52.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 45.03 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.59 | |||||
| 9-Day RSI | 41.53 | |||||
| 14-Day RSI | 49 | |||||
| 3-1 Month Momentum % | 21.05 | |||||
| 6-1 Month Momentum % | 28.67 | |||||
| 12-1 Month Momentum % | -26.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.4 | |||||
| Quick Ratio | 15.4 | |||||
| Cash Ratio | 14.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -43.51 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -3183.2 | |||||
| ROE % | -151.46 | |||||
| ROA % | -49.7 | |||||
| ROIC % | -1009.27 | |||||
| 3-Year ROIIC % | -1396.4 | |||||
| ROC (Joel Greenblatt) % | -1936.07 | |||||
| ROCE % | -48.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 78.26 | |||||
| PB Ratio | 4 | |||||
| Price-to-Tangible-Book | 4 | |||||
| EV-to-EBIT | -1.87 | |||||
| EV-to-EBITDA | -1.88 | |||||
| EV-to-Forward-EBITDA | -1.83 | |||||
| EV-to-Revenue | 73.59 | |||||
| EV-to-Forward-Revenue | 6.81 | |||||
| EV-to-FCF | -2.31 | |||||
| Price-to-Net-Current-Asset-Value | 4.29 | |||||
| Price-to-Net-Cash | 5.45 | |||||
| Earnings Yield (Greenblatt) % | -53.48 | |||||
| FCF Yield % | -33.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIST
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Milestone Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1 | ||
| EPS (TTM) ($) | -0.81 | ||
| Beta | 0.18 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.21 | ||
| Volatility % | 69.02 | ||
| 14-Day RSI | 49 | ||
| 14-Day ATR ($) | 0.103424 | ||
| 20-Day SMA ($) | 1.84925 | ||
| 12-1 Month Momentum % | -26.69 | ||
| 52-Week Range ($) | 1.12 - 2.93 | ||
| Shares Outstanding (Mil) | 53.33 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Milestone Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Milestone Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Milestone Pharmaceuticals Inc Frequently Asked Questions
What is Milestone Pharmaceuticals Inc(MIST)'s stock price today?
The current price of MIST is $1.80. The 52 week high of MIST is $2.93 and 52 week low is $1.12.
When is next earnings date of Milestone Pharmaceuticals Inc(MIST)?
The next earnings date of Milestone Pharmaceuticals Inc(MIST) is 2025-03-21 Est..
Does Milestone Pharmaceuticals Inc(MIST) pay dividends? If so, how much?
Milestone Pharmaceuticals Inc(MIST) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers